Gait Assessment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Other authors

Institut Català de la Salut

[Llauradó A, Quintana M, Vidal-Taboada JM, Restrepo-Vera JL, Alemañ J, López-Diego V, Salvadó M, Sanchez-Tejerina D, Sotoca J, Juntas-Morales R] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gratacós-Viñola M, Raguer N] Servei de Neurofisiologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-05-13T08:09:14Z

2024-05-13T08:09:14Z

2024-04-08



Abstract

Assessment; Chronic inflammatory demyelinating polyradiculoneuropathy


Evaluación; Polirradiculoneuropatía desmielinizante inflamatoria crónica


Avaluació; Poliradiculoneuropatia desmielinizant inflamatòria crònica


Background and Aims. Gait impairment is a common manifestation of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). However, clinicians lack an effective monitoring tool, as no gait test has been validated for CIDP. The aim of this study was to determine the usefulness of three tests in monitoring the clinical course of patients with CIDP: Timed Up and Go (TUG), 10-Meter Walk Test (10MWT), and 30-Second Chair Stand (30SCS). Methods. This is a prospective, single-center observational study. We included newly diagnosed CIDP patients starting treatment or relapsed CIDP patients requiring new treatment. We monitored the clinical course using CIDP-validated clinical scales and correlated changes in clinical status with the results of the gait tests. A ROC curve was developed, and we chose the cut-off point on each scale with the best specificity and sensitivity to detect change in clinical status. Results. A total of 20 patients have been recruited. The 3 tests show a statistical correlation with objective clinical improvement. In patients who have showed clinical improvement during the follow-up examination, a mean reduction of 4.8 seconds in TUG and 2.6 in 10MWT and a gain of 3 repetitions in 30SCS have been observed. The optimal cut-off points for each test were seconds, seconds, and repetition. The TUG test has the highest sensitivity (82.6%), and the 30SCS test has the highest specificity (100%) for detecting clinical improvement. Conclusions. The study found that the TUG and 30SCS tests could become effective tools for monitoring treatment response in CIDP patients.

Document Type

Article


Published version

Language

English

Publisher

Wiley

Hindawi

Related items

Acta Neurologica Scandinavica;2024

https://doi.org/10.1155/2024/7037704

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)